Overview

Safety and Efficacy of Pre-emptive Tapentadol vs Pregabalin in Post Operative Pain Following Surgery

Status:
Completed
Trial end date:
2020-05-19
Target enrollment:
0
Participant gender:
All
Summary
Preemptive analgesia is a treatment modality which starts even before the surgery, so that the central sensitization is prevented due to incisional injury at the time of surgery, so it covers the period of surgery and initial post-operative period preventing the development of central sensitization. Gabapentinoid compounds are gabapentin and pregabalin which have been extensively used in seizure disorder patient. Role of gabapentinoid compounds in the management of pain, as a pre-emptive analgesia is yet to be completely evaluated in post operative pain. Opioids have always been the preferred drugs to manage post operative pain. Since opioids have major side effects of nausea vomiting associated with its treatment their use comes with management of these side effects. Currently, diagnostic and therapeutic approaches to manage pain experienced by individuals are limited especially because there's a lack of bio-markers predictive of therapeutic outcome. In search of an objective method for pain measurement, as pain has always been subjective and it is perceived by different people differently the study will also include finding the use of COX(cyclo-oxygenase)-2 as a bio-marker of pain in post-operative patients. Although several randomized clinical trials and met-analyses have been conducted comparing the safety and efficacy of tapentadol or pregabalin in post-operative pain, there is no head to head clinical trial conducted comparing the preemptive use of two drugs for postoperative pain following total knee arthroplasty (TKA). Hence the present study is planned.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
All India Institute of Medical Sciences, Bhubaneswar
Treatments:
Pregabalin
Tapentadol
Criteria
Inclusion Criteria:

- 1. Patients both males and females undergoing total knee arthroplasty surgery. 2.
Patients are capable of providing an informed consent. 3. Age group between 18-75
years.

Exclusion Criteria:

- 1.Patients with asthma, COPD or any other respiratory disease. 2. Persistent nausea
and vomiting at time of randomization 3. Epilepsy. 4. Treated with mono amine oxidase
inhibitors, tricyclic antidepressants, serotonin norepinephrine re-uptake inhibitors,
gabapentinoids.

5. Patient with known neurological/ neuropsychiatric disorders. 6. Drug or alcohol
abuse history 7. Opioid tolerance or opioid dependence. 8. Known history of opioid
allergy or pregabalin allergy. 9. Renal disease (creatinine >1.5mg/dl) 10. Liver
disease (total bilirubin >1.5mg/dl) 11. Pregnancy and lactation. 12. Cardiovascular
insufficiency. 13. Patient with potential serotonin syndrome. 14. Patient with history
of constipation and prone to paralytic ileus.